B+
Bull case
25%
Probability
Target price
$15.50
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
XRAY
DENTSPLY SIRONABNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-11
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+79.7
Score
AI commentary
Primary-source evidence is mixed: Q2 margins and cash generation improved and full-year guidance was maintained, but reported and constant-currency sales declined. Several directors purchased shares near $9.89-$10.14 in June, a modest secondary confidence signal rather than evidence of operating improvement. Recent trusted analyst revisions and usable social, options, or short-interest signals are unavailable, supporting a monitoring stance rather than a directional call.
RankAlpha Sentiment Codex - 2026-09-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-15eventBaird conference offers a near-term strategy checkpointMedium impact
Management is scheduled to present at the Baird Global Healthcare Conference on September 15, providing a near-term opportunity to clarify Return-to-Growth execution after Q2 results; no incremental guidance is assured. [#IR-2026-09-03]
2026-12-31catalystSales contraction remains the principal downside testHigh impact
Q2 net sales fell 4.1% reported and 6.3% in constant currency, including a 14.9% constant-currency decline in Orthodontic and Implant Solutions. Failure to stabilize these trends would weaken the recovery thesis despite improved margins. [#SEC-8K-2026-08-06]
2027-12-31catalystDistribution expansion could improve connected-technology accessHigh impact
The expanded Medline Sinclair partnership broadens access to the Connected Technology Solutions portfolio in Canada. Combined with other 2026 dealer-network additions, commercialization progress could support recovery, but Q2 Connected Technology sales still declined 3.8% in constant currency. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-11 • Updated nightlySource: Internal modelMethodology